Clinical phenotypes and biomarkers in chronic urticaria

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-03-07 DOI:10.1016/j.cca.2025.120233

Aray Batyrbayeva , Zhanat Ispayeva , Marat Pashimov , Jamilya Kaibullayeva , Madina Baidildayeva , Uldana Kapalbekova , Elmira Tokmurzayeva , Olga Plakhotina , Arailym Maldybayeva , Asem Salmanova , Leila Kuandykova , Kamila Turebekova

{"title":"Clinical phenotypes and biomarkers in chronic urticaria","authors":"Aray Batyrbayeva , Zhanat Ispayeva , Marat Pashimov , Jamilya Kaibullayeva , Madina Baidildayeva , Uldana Kapalbekova , Elmira Tokmurzayeva , Olga Plakhotina , Arailym Maldybayeva , Asem Salmanova , Leila Kuandykova , Kamila Turebekova","doi":"10.1016/j.cca.2025.120233","DOIUrl":null,"url":null,"abstract":"<div><div>The medical field faces considerable challenges in treating chronic urticaria (CU), which includes both chronic spontaneous urticaria (CSU) and chronic inducible urticaria, owing to its varied nature. The complexity of this condition stems from multiple factors: varying disease mechanisms, different ways in which symptoms manifest, and inconsistent treatment outcomes. Although both forms of CU display hives that persist beyond six weeks, they have distinct causes and progression patterns. This study examines CSU specifically, exploring its various manifestations and associated biological indicators. Currently, there is a pressing need to identify reliable, accessible biomarkers for CSU to enhance diagnosis and develop targeted treatments. Better insights into how specific disease patterns are related to biological markers would significantly improve our understanding of CSU development and enhance patient treatment approaches.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"571 ","pages":"Article 120233"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125001123","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The medical field faces considerable challenges in treating chronic urticaria (CU), which includes both chronic spontaneous urticaria (CSU) and chronic inducible urticaria, owing to its varied nature. The complexity of this condition stems from multiple factors: varying disease mechanisms, different ways in which symptoms manifest, and inconsistent treatment outcomes. Although both forms of CU display hives that persist beyond six weeks, they have distinct causes and progression patterns. This study examines CSU specifically, exploring its various manifestations and associated biological indicators. Currently, there is a pressing need to identify reliable, accessible biomarkers for CSU to enhance diagnosis and develop targeted treatments. Better insights into how specific disease patterns are related to biological markers would significantly improve our understanding of CSU development and enhance patient treatment approaches.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.